CD274 and neoplasm: We aimed here to identify pre-treatment soluble immune checkpoint and circulating tumor antigens as surrogate/predictive markers in TPD-L1 expressing patients and to determine the role of soluble markers as predictors of response in anti-PD-1/PD-L1 treated NSCLC patients.